Entrar Registro gratuito

Akari Therapeutics Plc Razão de venda descoberta

Qual é o Razão de venda descoberta de Akari Therapeutics Plc?

O Razão de venda descoberta de Akari Therapeutics Plc é 0.65

Qual é a definição de Razão de venda descoberta?



Razão da venda descoberta é o número de acções vendidas a descoberto dividido pelo volume médio diário.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

Razão de venda descoberta de empresas na Setor Health Care em NASDAQ em comparação com Akari Therapeutics Plc

O que Akari Therapeutics Plc faz?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Empresas com razão de venda descoberta semelhantes a Akari Therapeutics Plc